Combination of Mangiferin and Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Impaired Glucose Tolerance in Streptozotocin-Diabetic Rats
- 1 January 2012
- journal article
- Published by S. Karger AG in Pharmacology
- Vol. 90 (3-4), 177-182
- https://doi.org/10.1159/000342128
Abstract
In this study, we combined the dipeptidyl peptidase-4 inhibitor sitagliptin with the antidiabetic drug mangiferin to examine the effects on active glucagon-like peptide-1 (GLP-1) and glucose tolerance in streptozotocin-diabetic rats. Active GLP-1 levels were measured by an ELISA kit. Insulin levels were measured by an RIA kit. Islet morphology was determined by double immunolabeling. Sitagliptin (1 mg/kg) or mangiferin (20 mg/kg) single treatment improved glucose tolerance during an oral glucose tolerance test. In addition, the combination therapy improved glucose tolerance with an increase in plasma insulin level and active GLP-1 levels. Islets from combination-treated diabetic rats had markedly increased β-cell/islet area ratio compared with islets from the diabetic or single-treatment rats. In conclusion, these results indicate that the combination therapy is useful as a therapeutic agent for impaired glucose tolerance and type 2 diabetes.Keywords
This publication has 15 references indexed in Scilit:
- Beneficial effects of mangiferin on hyperlipidemia in high‐fat‐fed hamstersMolecular Nutrition & Food Research, 2011
- Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetesExpert Opinion on Investigational Drugs, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Diabetes and obesity: the twin epidemicsNature Medicine, 2006
- Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant RatsJournal of Pharmacology and Experimental Therapeutics, 2005
- Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetesDiabetologia, 2005
- Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic ratsJournal of Ethnopharmacology, 2005
- Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in ratsToxicology, 2002
- Protective effects of Mangifera indica L. extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in micePharmacological Research, 2000
- Antitumor, Immunomodulatory and Anti-HIV Effect of Mangiferin, a Naturally Occurring GlucosylxanthoneChemotherapy, 1996